Skip to content
Torrent Pharmaceuticals logo

Torrent Pharmaceuticals

TORNTPHARM NSE
₹4,689.50 +78.50 (+1.70%)
Market Cap
₹1,78,374 Cr
P/E
77.80
View as Markdown
MCP
Close 20 Nov 2026 ₹4,689.50 1Y +971.10 +26.1%
Start ₹3,718.40

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.20%
Debt to Equity
0.77
EPS (TTM)
₹60.28
Book Value
₹483.03
Market Cap
₹1,78,374 Cr
P/E (TTM)
77.80
P/B
9.71
ROE
27.40%
Dividend Yield
0.82%
EBITDA
₹4,465 Cr
52W High
₹5,250.00
52W Low
₹3,672.30
Day Range
₹4,611.20 – ₹4,689.50
Volume
2,00,042

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Torrent Pharmaceuticals peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
Torrent Pharmaceuticals (this company)
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Median 7 companies1,884.9041.441,23,9805.070.57%16.50%17.80%28,1392,855

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

Category scores

Quality
73
Strong
Returns, margins, earnings quality 22% weight
Valuation
46
Average
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
15
Poor
Solvency, leverage, coverage 9% weight
Momentum
19
Poor
Trend strength, vol-adjusted 12% weight
Ownership
46
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • Company has been maintaining a healthy dividend payout of 57.8%

Weaknesses

3
  • Stock is trading at 9.71 times its book value
  • Promoter holding has decreased over last quarter: -7.53%
  • The company has delivered a poor sales growth of 11.8% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish775
OscillatorsBearish270
Moving AveragesNeutral505

Key readings

RSI (14)
50.46
Neutral
MACD (12,26,9)
−9.79
Bearish
SMA (50)
4,730.52
Bearish
SMA (200)
4,564.14
Bullish

As of

Analyst Rating

Based on 29 analysts
BUY79%

23 of 29 analysts rate Buy, 5 Hold, 1 Sell.

As of

BUY
23
79%
HOLD
5
17%
SELL
1
3%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+7.65%
5Y+11.80%
3Y+13.27%
1Y+21.40%
TTM+42.06%

Net profit

Net profit growth by window
10Y+2.12%
5Y+11.30%
3Y+19.75%
1Y+11.88%
TTM−1.92%

Operating cash flow

Operating cash flow growth by window
10Y+0.98%
5Y+8.56%
3Y+8.48%
1Y+16.94%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−8.27 pp
5Y+1.62 pp
3Y+3.06 pp
1Y+0.29 pp
TTM+0.58 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5,816 Cr
Mar 2018₹5,950 Cr
Mar 2019₹7,673 Cr
Mar 2020₹7,939 Cr
Mar 2021₹8,005 Cr
Mar 2022₹8,508 Cr
Mar 2023₹9,620 Cr
Mar 2024₹10,728 Cr
Mar 2025₹11,516 Cr
Mar 2026₹13,980 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹934 Cr
Mar 2018₹678 Cr
Mar 2019₹436 Cr
Mar 2020₹1,025 Cr
Mar 2021₹1,252 Cr
Mar 2022₹777 Cr
Mar 2023₹1,245 Cr
Mar 2024₹1,656 Cr
Mar 2025₹1,911 Cr
Mar 2026₹2,138 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,654 Cr +5.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 16 Nov 2026
AI opinion · based on fundamentals
Risk high

Torrent Pharmaceuticals trades at ₹4,691.20 as of 2026-11-16 with a market cap of ₹1,78,438 crore. The company commands a PE of 77.82x and a price-to-book of 9.71x, reflecting premium valuations, while delivering a 3-year ROE of 26% and TTM sales growth of 42%. Debt-to-equity stands at 1.79, and promoter holding declined by 7.53% in the last quarter.

Bull Case 7
  • TTM revenue growth of 42% marks a sharp acceleration compared to the 5-year compounded sales growth of 12%, signalling strong recent top-line momentum
  • 3-year ROE of 26% and 5-year ROE of 24% demonstrate consistently high capital efficiency well above industry averages
  • Stock price CAGR of 31% over 3 years and 27% over 5 years reflects sustained long-term wealth creation for shareholders
  • Healthy dividend payout ratio of 57.8% indicates shareholder-friendly capital allocation, with a current dividend yield of 0.81%
  • 3-year compounded profit growth of 22% shows meaningful earnings expansion in the medium term
  • Last year ROE of 27% is the highest in the reported range, suggesting improving profitability trends
  • The stock trades roughly 11% below its 52-week high of ₹5,250, offering a pullback from peak levels while remaining 28% above the 52-week low of ₹3,672.30
Bear Case 8
  • PE of 77.82x is significantly elevated, demanding sustained high earnings growth to justify the premium valuation
  • Debt-to-equity ratio of 1.79 is relatively high for a pharmaceutical company, increasing financial risk and interest burden
  • Promoter holding decreased by 7.53% over the last quarter, which may signal reduced insider confidence
  • Price-to-book of 9.71x is steep, meaning investors are paying nearly ten times the book value per share
  • TTM profit growth of 0% stands in stark contrast to the 42% sales growth, indicating margin compression or one-off cost pressures eroding bottom-line performance
  • 10-year compounded profit growth of just 2% suggests long-term earnings have barely kept pace with inflation despite an 8% sales CAGR over the same period
  • ROCE of 9.06% is modest relative to ROE of 12.16%, and the gap hints at leverage-driven returns rather than pure operational efficiency
  • Potential capitalisation of interest costs may be flattering reported profitability, masking the true cost structure

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

20h ago

TL;DR: A quiet week for Torrent Pharma with no major catalysts. The ₹3.12 crore GST penalty is minor relative to the company's scale and relates to a legacy JB Chemicals matter under appeal. Scheduled NCD redemption reflects orderly debt management. Near-term direction will likely depend on broader sector sentiment and any updates shared at the upcoming investor meets in mid-November.

Headwinds 1
  • GST penalty on legacy acquisition Nov 5

    Torrent Pharma received a ₹3.12 crore GST penalty order from Tiruvallur authorities related to pre-acquisition JB Chemicals matters. The company plans to appeal the order.

Neutral 2
  • ₹100 Cr NCD redemption on schedule Nov 9

    Torrent Pharmaceuticals redeemed ₹100 crore in unlisted secured redeemable non-convertible debentures on November 9, 2026, as per the scheduled repayment timeline.

  • Investor conferences in mid-November Nov 6

    Torrent Pharma will participate in investor conferences in Mumbai on November 16 and 17, 2026, signaling continued engagement with the institutional investor community.

Quarterly Results

₹ Cr
TORNTPHARM quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
2,660
2,732
2,745
2,859
2,889
2,809
2,959
3,178
3,302
3,303
4,197
4,921
4,979
Expenses
1,835
1,863
1,862
1,955
1,950
1,895
1,995
2,146
2,219
2,215
2,841
3,257
3,313
Operating Profit
825
869
883
904
939
914
964
1,032
1,083
1,088
1,356
1,664
1,666
OPM %
31%
32%
32%
32%
32%
33%
33%
32%
33%
33%
32%
34%
33%
Other Income
26
−33
31
24
−16
33
−18
−37
−27
−23
−17
−33
−10
Interest
91
80
80
75
64
57
56
56
48
45
236
305
300
Depreciation
201
213
203
197
198
199
201
201
204
206
508
593
609
Exceptional Items
—
88
—
—
—
—
−24
—
−13
—
−66
—
−10
PBT
559
631
631
656
661
691
665
738
791
814
529
733
737
Tax %
31%
30%
29%
30%
31%
27%
25%
26%
25%
22%
31%
23%
28%
Net Profit
386
443
449
457
453
503
498
548
591
635
364
566
534
EPS (₹)
11.41
13.09
13.27
13.50
13.38
14.86
14.71
16.19
17.46
18.76
10.76
16.72
14.04
YoY Sales growth
16
10
10
10
9
3
8
11
14
18
42
55
51

Profit & Loss

₹ Cr
TORNTPHARM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
4,636
6,687
5,816
5,950
7,673
7,939
8,005
8,508
9,620
10,728
11,516
13,980
17,400
Expenses
3,616
3,954
4,438
4,601
5,690
5,769
5,524
6,077
6,778
7,360
7,795
9,421
11,626
Operating Profit
1,020
2,733
1,377
1,349
1,983
2,170
2,480
2,431
2,842
3,368
3,721
4,558
5,774
OPM %
22%
41%
24%
23%
26%
27%
31%
29%
30%
31%
32%
33%
33%
Other Income
286
32
223
299
57
122
57
197
45
58
23
−182
−159
Interest
175
184
206
308
504
451
353
255
333
354
252
385
886
Depreciation
191
238
307
409
618
654
658
662
707
808
795
1,119
1,916
Exceptional Items
—
—
—
—
−357
—
—
−485
—
88
−24
—
—
PBT
940
2,343
1,088
931
562
1,187
1,526
1,226
1,847
2,352
2,673
2,872
2,813
Tax %
20%
26%
14%
27%
22%
14%
18%
37%
33%
30%
28%
26%
—
Net Profit
751
1,733
934
678
436
1,025
1,252
777
1,245
1,656
1,911
2,138
2,099
EPS (₹)
22.19
51.22
27.59
20.04
12.89
30.28
36.99
22.97
36.79
48.94
56.47
63.92
60.28
Div. Payout %
25%
34%
25%
35%
66%
53%
47%
105%
60%
57%
57%
59%
—
Sales growth
11
44
−13
2
29
3
1
6
13
12
7
21
42

Balance Sheet

₹ Cr
TORNTPHARM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
85
85
85
85
85
85
85
85
169
169
169
169
190
Reserves
2,406
3,409
4,266
4,538
4,640
4,739
5,753
5,868
6,029
6,687
7,421
8,219
18,183
Borrowings
2,740
2,352
2,510
6,462
6,038
5,784
4,874
4,070
5,369
4,022
3,202
15,026
14,107
Other Liabilities
2,589
3,040
2,740
3,159
3,351
3,402
3,363
2,884
3,043
3,627
3,603
20,200
12,135
Total Liabilities
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
44,615
Fixed Assets
2,833
2,859
3,688
7,855
7,748
7,533
7,065
6,423
8,121
8,138
7,947
33,191
32,621
CWIP
678
1,042
519
647
617
712
889
630
765
361
478
641
404
Investments
298
780
804
492
353
2
181
226
199
173
156
948
2,160
Other Assets
4,011
4,206
4,589
5,249
5,395
5,763
5,940
5,628
5,524
5,834
5,815
8,833
9,430
Total Assets
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
44,615

Cash Flow

₹ Cr
TORNTPHARM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
810
2,742
1,009
894
1,798
1,393
2,005
1,803
2,368
3,266
2,585
3,023
Investing
−2,113
−869
−798
−4,677
−246
229
−444
−196
−2,335
−160
−549
−12,630
Financing
1,212
−1,435
−193
3,417
−1,314
−1,549
−1,651
−1,781
77
−2,780
−2,298
10,151
Net Cash Flow
−90
437
18
−366
238
73
−89
−174
110
327
−262
544
Free Cash Flow
574
2,150
523
105
1,138
990
1,671
1,607
1,953
2,967
1,991
2,386
CFO/EBITDA
85
121
101
87
105
77
88
91
97
112
86
84

Ratios

TORNTPHARM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
125
79
60
77
68
76
69
70
74
63
59
79
Inventory Days
275
314
318
429
318
362
456
368
298
310
334
338
Days Payable
472
523
356
447
345
345
351
250
224
284
239
254
Cash Conversion Cycle
−71
−130
21
59
42
93
174
188
147
89
154
163
Working Capital Days
29
−1
28
−80
−62
−52
−5
7
−33
−27
7
−26
ROCE %
27%
48%
19%
13%
13%
15%
17%
19%
20%
23%
27%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Torrent Pharmaceuticals insights

70 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 60.78%
  • FIIs 17.22%
  • DIIs 13.46%
  • Public 6.95%
  • Others 1.59%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Torrent Pharmaceuticals

What does Torrent Pharmaceuticals Ltd do?
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.
Where is Torrent Pharmaceuticals Ltd (TORNTPHARM) listed?
Torrent Pharmaceuticals Ltd trades as TORNTPHARM on the NSE and under code 500420 on the BSE.
Which sector does Torrent Pharmaceuticals Ltd belong to?
Torrent Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a market capitalisation of ₹1,78,374 Cr as of 20 Nov 2026, which places it in the Largecap band.
What is the PE ratio of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd trades at a PE ratio of 77.80 as of 20 Nov 2026, on earnings per share of ₹60.28, against a book value of ₹483.03 per share.
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
Over the last 52 weeks Torrent Pharmaceuticals Ltd has traded between ₹3,672.3 and ₹5,250 as of 20 Nov 2026.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd has a dividend yield of 0.82%.
What is the Return on Equity (ROE) of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd reported a return on equity of 27.40%. Its debt-to-equity ratio is 0.77.

Company Information

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.

CEO Mr. Aman Mehta
Employees 17,059
Listed 25 Nov 2002
Face Value ₹5
Shares Outstanding 38,03,67,856

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TORNTPHARM.md for Torrent Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More